X4 Pharmaceuticals Announces $125 Million Capital Infusion to Extend Cash Runway, Driving Growth and Innovation in Biopharmaceuticals Industry

Published / Modified May 09 2024
CSIMarket Team / CSIMarket.com

X4 Pharmaceuticals Secures $125 Million Non-Dilutive Capital to Extend Cash Runway into Late 2025

X4 Pharmaceuticals Inc. recently announced a major capital infusion of $125 million, which includes $105 million from the sale of a Priority Review Voucher and a $20 million drawdown from an existing loan facility. This infusion of non-dilutive capital will extend the company's projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI (mavorixafor).

Despite a sequential decrease in current liabilities during the first quarter of 2024, X4 Pharmaceuticals Inc's working capital ratio deteriorated to 3.9, falling below the company's average of 7.46. When compared to 61 other companies within the industry, X4 Pharmaceuticals Inc ranked lower in terms of working capital ratio in the first quarter of 2024. However, the company has shown improvement, with a ranking of 619 compared to 6.08 in the third quarter of 2023.

On a trailing twelve-month basis, X4 Pharmaceuticals Inc's cumulative working capital ratio decreased to 5.59 in the first quarter of 2024, below the company's average. When compared to other companies in the industry, X4 Pharmaceuticals Inc ranked lower, with a deterioration in overall ranking from 3374 in the third quarter of 2023 to 3646 in the past twelve months.

Overall, the capital infusion from the sale of the Priority Review Voucher and drawdown from the existing loan facility will provide X4 Pharmaceuticals Inc with the necessary funds to continue its operations and advance its pipeline of innovative therapies. The company's focus on securing non-dilutive capital demonstrates its commitment to strategic financial management and sustainable growth.


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com